NEW YORK (GenomeWeb) – Selah Genomics, a subsidiary of EKF Diagnostics, today announced a collaboration with Greenville Health System, DecisionQ, and Becton Dickinson to integrate next-generation sequencing into the care of colon cancer patients.

As part of the 18-month partnership, Selah Genomics will use its PrecisionPath NGS technology to profile tumor samples provided by the Institute for Translational Oncology Research (ITOR), part of GHS's Cancer Institute. The samples, from colon cancer patients, will be provided with full clinical annotation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Sponsored by

This webinar will address a range of methods for optimizing small RNA library preparation.

Sponsored by

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Sponsored by

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.